Post-marketing commitment tracking, explained.

Post-marketing commitments in plain words: the homework that comes with an approval

One FDA letter's path from the mailbox to a closed commitment

1. The agency writes something downFDA's October 2 letter approves Veltrimab for Crohn's disease and adds a pediatric study, PMR 4512-7, with its protocol due in June 2027.
2. Someone finds it and records itThe exact wording, the page, every date. This is where the May promise in the Type C minutes was lost.
3. Owners are named and watchedA regulatory owner and a functional owner (the person whose team does the work), with internal targets well before the agency date.
4. Status goes back to the agencyAnnual status tables, 180-day reports on a confirmatory trial, renewal updates in Europe.
5. The agency closes itFDA writes that the item is fulfilled or released. Until that letter arrives, it stays open.

Steps 2, 3 and 4 are the subject of this guide. The company, products and dates in this example are fictional.

Why a submitted report stays open, and three more commitment surprises

What PMR, PMC, annual status report and fulfilled mean

Fourteen terms are defined in the one-page summary.

PMR vs PMC vs a promise in the minutes: three kinds of post-approval duty

In shortA PMR is required by law. A PMC is agreed in writing. A promise is an undertaking the company gave a regulator in a meeting or a reply, with no formal number. FDA's public data tracks the first two, apart from CMC commitments; only your own reading finds the third.

The difference between the first two is legal. FDA can require a study under four authorities, listed below, and missing a requirement can bring enforcement. A PMC has no such statute behind it, though FDA still tracks it and many applicants must report on it each year.1

The third kind has no agency term at all. "Promise" is this guide's word for a dated undertaking that appears only in minutes, a written response or an email. It has no number and no line in any public database, and the only file that holds it is the correspondence archive. The cards below use this guide's fictional company, Northwind Bio, whose medicines include Veltrimab and Dravenzo.

The four authorities behind FDA's postmarketing requirements

21 CFR means title 21 of the Code of Federal Regulations, where FDA's rules sit.

The FDA rules behind PMR and PMC tracking, and what changed in 2026

In shortSection 506B of the FD&C Act and two regulations set the yearly report. Later laws added required studies, pediatric studies and 180-day reports. In 2026 Congress opened PREA failures to enforcement under section 303, the Act's penalties section, and FDA finalized its formal meetings guidance, the document that says minutes are the official record.

FDA's guidance documents are its current thinking and do not bind anyone. The statutes and regulations do.

Regulatory commitments live in five kinds of document, and only one announces them under a heading

In shortApproval letters announce their requirements under clear headings, so they get entered. Minutes, question responses and local certificates do not, and they are filed as correspondence. Dates also come in several forms, from a calendar day to "after 30 lots", and each needs a decision when it goes on a tracker.

A supplement is a filing that changes an approved application. EMA is the European Medicines Agency, and CHMP is its committee for human medicines.

Why a promise in FDA minutes is easy to miss and hard to dismiss

FDA holds several kinds of formal meeting with sponsors, the companies behind a medicine: Type A, Type B, Type B (end of phase), Type C, Type D and INTERACT. It issues "the official, finalized minutes to the requester within 30 calendar days after the meeting", and its guidance says "FDA's minutes are the official records of meetings".10

If you disagree with the minutes, you contact the FDA project manager and, if that does not settle it, send a written description of the disagreement. FDA then confirms the minutes stand or adds an addendum.10 So the record is what FDA wrote, unless you objected.

Teams read minutes for the answer to their question, and for the action items. A dated promise can sit in the discussion paragraph just above. That is how it happens in this guide's example: on page 2 of the Type C minutes, the action items list final minutes and a packaging supplement, while the sentence "The sponsor agreed to submit a shipping validation report… to the BLA by March 31, 2027" sits at the end of Question 3.

Five forms a due date can take on a postmarketing commitment

The annual status report under 21 CFR 314.81 and 601.70, worked through

In shortFor each open study, the report gives the description, the original and any revised schedule, one of five status words, and an explanation. It is due within 60 days of the approval anniversary. Status is judged against the original schedule, so moving a date rarely clears the word "delayed".

What each row of a PMR and PMC status table must say

The two regulations ask for the same things: the applicant's name, the product, the application and supplement number, the approval date, the date of the commitment, a description of the study, its schedule, its current status and an explanation of that status.4,5 The explanation is the hard part. For NDAs it covers patient enrollment against the planned total and the reasons for any schedule change.5 Those facts sit with clinical, CMC and real-world evidence teams, so someone has to go and get them, one sentence at a time.

FDA lets applicants ask for an alternate reporting date, and some use one to report on several applications at once.1 Write the granted date on the record. An alternate date that lives in one person's memory is a late report waiting to happen. Pediatric studies on a BLA carry a further yearly report under 21 CFR 601.28, also within 60 days of the anniversary.12

The five status words and the sixth state that closes the item

What a CMC commitment on the same letter does differently

A single approval letter can list clinical and CMC commitments side by side, and they part ways at reporting. FDA's report states that the status of PMCs on chemistry, manufacturing and production controls is "not required to be reported" under 21 CFR 314.81(b)(2)(vii) and 601.70, and they are absent from FDA's database and its performance report.1 For NDAs, section 314.81(b)(2)(viii) covers them instead.5

They still have dates, and a missed one still reaches the FDA division that reviews your next supplement. Keep them on the same record, and report them by the route your letter names.

Accelerated approval confirmatory trials and the 180-day progress report clock

In shortA drug on accelerated approval owes a progress report on its confirmatory trial at least every 180 days, and FDA posts what it receives. FDA's fiscal 2024 report describes two reports a year: one 180 days after approval and one with the annual status report. A schedule counted from each last date drifts earlier on the calendar, so agree your convention with your FDA division and write it down.

Accelerated approval lets FDA approve a drug on an early measure that is likely to predict benefit, on the condition that the company runs a study to confirm the benefit. If the confirmatory trial fails, FDA has procedures that can remove the drug from the market.18

The 2022 reforms, section 3210 of the Food and Drug Omnibus Reform Act (FDORA), tightened this in several ways.7,19 The law now says the sponsor "shall submit to the Secretary a report… not later than 180 days after the approval of such drug and not less frequently than every 180 days thereafter", and that FDA "shall promptly publish" what is reported on its website.7

FDA may require the study to be underway before approval or within a set time after it, and failure to run a required study "with due diligence" is a ground for expedited withdrawal.19

The 180-day report is short, and it often has its own owner, even when one of the two goes in with the annual report. It gives trial status, enrollment and any change to the timeline, usually with facts from a clinical team busy running that trial. The same trial often appears in other markets' conditions too, with other dates, as the next section shows.

How EU specific obligations, post-authorisation measures and other markets' conditions add their own dates

In shortEMA sorts post-authorisation measures into categories with their own codes and due dates. A conditional authorisation lasts a year, and the renewal application is due six months before it expires, with an update on the specific obligations. Other regulators work in similar ways, so one trial can owe different dates in five markets.

A conditional marketing authorisation lets the EU approve a medicine for an unmet need on less complete data. It is "valid for one year" and "can be renewed annually", and the holder must "fulfil specific obligations within defined timelines".21 Commission Regulation 507/2006 sets the frame: the obligations and their timeframe are spelled out, and the renewal goes in at least six months before expiry.22

EMA adds that with no application the authorisation "will expire automatically", and that the interim report should give details for each specific obligation.23 From 2006 to June 2016, 30 medicines received one, and it took an average of four years to generate the further data needed to convert to a full authorisation.24 We did not find a newer count that we could read; check EMA's annual reports.

EMA uses other codes too; its questions and answers give the full list.17

Changing a date in the EU has its own procedure. The holder submits the data on the timeframe the committee set and may propose dates, which the committee must agree. Changing the due date of a specific obligation or an Annex II condition is a type IB variation (a minor change filed with EMA), category C.9.b.17 A medicine authorised under exceptional circumstances goes through an annual re-assessment, filed on the anniversary of the Commission decision, adjustable by up to two months either way.23

How the UK, Canada, Switzerland and Australia handle approval conditions

The example's register also holds local conditions from PMDA in Japan, TGA in Australia and ANVISA in Brazil. Those entries, including their wording and dates, are fictional; check each agency's current rules for your own products.

This is why teams link one study across markets. If the US and EU leads each keep their own list, each sees a coherent plan, and nobody sees that Europe needs the final report on June 30, 2027 while the US plan writes it for September. A slip in the trial moves every line at once.

Why post-approval commitments slip: twelve errors and where each one starts

In shortMost failures start months before the agency date: a sentence never entered, an owner who left, an internal milestone nobody watched. FDA's own count shows about one annual status report in five arrived late or not at all in fiscal 2024. The errors below are our reading of how the rules and the documents interact; no public study ranks them.

What a missed PMR or PMC date risks: public status, penalties and withdrawal

In shortThe first consequence is visibility: FDA's public database and annual report. Beyond that come a violation finding for a required study, civil money penalties, misbranding and, since 2026, section 303 action on PREA studies. Accelerated approvals also face a faster route to withdrawal. Patients carry the real cost when pediatric or confirmatory data arrive late.

Where the PMRs from each fiscal year stand: delayed, open or closed

Enforcement figures tell a small part of the story. A late pediatric study can mean children go on being treated without a tested dose. A late confirmatory trial means patients and payers rely longer on an unconfirmed benefit: the inspector general counted more than $18 billion in Medicare and Medicaid spending from 2018 through 2021 on the 18 drugs behind the applications with trials past their original dates.20 And for the company, every supplement filed to a division that is waiting on a late report starts with that conversation.

How many postmarketing requirements are open: FDA's counts, and what nobody publishes

In shortOn September 30, 2024, 402 applicants held 2,022 open PMRs and PMCs across 826 applications, or about five per applicant. FDA adds roughly 300 new requirements a year. Nobody publishes a market size for tracking tools, or how much time the work takes.

Lost promises, table hours, software share: figures nobody publishes, and how to get yours

A quick outside check on your own record costs nothing: download FDA's database, filter to your applications, and compare every row and status with your tracker. Explain each difference; some will be lag, because FDA reviews what it receives before it updates a status.1,2

What AI can do for regulatory commitments management, and what regulators expect

In shortReading letters and minutes for undertakings, comparing them with a register and drafting status text are good jobs for software, because each result can be checked against its page. FDA's draft AI guidance leaves out internal workflows that have no effect on patients, quality or study reliability. People still sign, and electronic signature and audit trail rules still apply to the records.

The work that moves to software, and the decisions that stay with named people

Who owns a health authority commitment today, from approval letter to status table

In shortRegulatory affairs owns the list, functional teams own the work, and regulatory operations compiles the reports. Teams commonly keep the record in a spreadsheet or a RIM module, typed by hand from approval letters. The hours pile up at report time, chasing status from people who have other jobs.

Regulatory lead, operations, functional owners and compliance: who carries what

Spreadsheet, RIM module or outside help: three ways teams keep the record

Three new FDA letters on October 7, and the shipping promise nobody tracked

In shortThis is the example from the top of the page, inside the product. Omar Haddad, the regulatory lead, clicks once. Specialist agents read three new FDA letters, put six new dates on the timeline as proposals, and re-read Veltrimab's 63 minutes and responses on file. They find one promise from May that was never tracked. Omar signs it onto the timeline, and Lena Ortiz, the CMC owner, will hear about it 90 days ahead.

1

Every date owed to an agency, on one timeline by product

Omar opens the commitment timeline: 29 open items, 4 products, 8 health authorities. Requirements are circles; commitments and promises are squares. Red means at risk. He clicks the red square on Veltrimab's lane: re-evaluate the limits on HMW species (high molecular weight, meaning clumped protein), due October 31, 24 days away.

The panel on the right shows where that date came from: the approval letter, page 2, in the agency's words, with 10/2026 highlighted. It also shows why the item is red: 21 of the 30 commercial lots have been made.

2

"Read 3 new letters": five steps you can watch

Three FDA letters are waiting. Omar clicks "Read 3 new letters". The Correspondence Reader identifies the S-008 supplement approval, the Dravenzo fulfillment letter and the Type B minutes. The Commitment Extractor finds 6 items, each with its page and exact words, and sets one standing reminder aside. The Change & Duplicate Checker sorts them: 4 new, 1 change to CMT-101, PMR 3990-1 fulfilled.

Because Veltrimab just received a new approval, the Promise Finder re-reads that product's 63 minutes and responses on file.

3

Proposed dates appear dashed until Omar signs

The new dates land on the timeline as dashed, violet proposals. The new pediatric Crohn's study, PMR 4512-7, has its final protocol due June 2027, nine months out, with study completion 06/2030 and the final report 12/2030. On Dravenzo, two promises from the Type B minutes appear the same way. Nothing is final yet.

4

Five promises outside approval letters, and one never tracked

Below the timeline, a panel lists what the company told agencies in meetings and replies. Two Health Canada responses are already on the timeline as CMT-111 and CMT-308. Two come from the new Dravenzo minutes, waiting for a signature. The fifth is at the top, marked "Never tracked · filed Jun 19".

5

The sentence, the page and why it was missed

Omar clicks it. The panel shows the Type C minutes of June 12, page 2, the sentence with March 31, 2027 highlighted, and a plain note: a dated promise in the discussion of Question 3, filed on June 19 with no timeline entry. The source opens at the passage, and the action items sit just below it, listing other things.

6

One signature puts CMT-116 on the timeline

"Add to the timeline" opens the promise with its date fixed by the minutes, Lena Ortiz as functional owner and the meaning of the signature: "I approve this timeline entry". The alerts are scheduled at 90, 60, 30 and 7 days before March 31, 2027: December 31, January 30, March 1 and March 24.

Omar signs. The promise becomes CMT-116, the open count goes from 29 to 30, and the panel now reads "On the timeline".

Reviewing the S-008 approval letter: new requirement, changed commitment, standing reminder

In shortThe letter opens beside what was found. Each item carries its page, a confidence figure and a reason. A new requirement is confirmed, a change shows old and new wording, and a standing reminder is set aside. Omar decides each one, and a change to an existing record also needs a compliance countersignature.

Four kinds of finding, and what each one asks of the regulatory lead

The commitments register, inherited items with no owner, and one study across five agencies

In shortBehind the timeline sits a register of every requirement, commitment, obligation, condition and promise. It filters by type, product, agency, owner and date. It shows who owns what, surfaces items that arrived in an acquisition with no owner, and links the same study across markets.

Catching a slipping commitment early: internal targets, a new date and a 180-day draft

In shortEvery morning the Deadline Monitor checks each milestone and internal target, alerts owners from 90 days out and raises a slip the day a target is missed. Moving a date takes a reason and two signatures. A report that is due soon can be drafted on the spot from the trial's status.

1

Three internal targets missed before the agency date

On CMT-106, the HMW species re-evaluation, the plan said 25 lots by June 30, 30 lots by August 31 and a data review by September 30. All three were missed, by 99, 37 and 7 days. The agency date is still 24 days off, so there is time to talk to FDA before it passes.

2

Requesting a new date takes a reason and two signatures

"Request a new date" opens a dialog. The Deadline Monitor and the Status Reporter draft the reason in the agency's terms: 21 of the 30 lots made, the 30th planned for February 2027, the supplement to follow, a proposed new date of May 31, 2027. Omar edits and signs; Dana Okafor countersigns. The dialog says the item will be reported as Delayed, which matches FDA's rule that status follows the original schedule.4

3

A 180-day progress report, drafted from the trial status

Talvoren's progress report 3 is due in 7 days and no draft exists. The Status Reporter reads the trial status (612 patients, enrollment complete April 16, 71% of final-analysis events), compares it with report 2, and writes the report in four sections with five citations. Omar can ask Dr. Maya Chen, the clinical owner, to check the facts, then sign and mark it submitted.

Drafting the annual status table for BLA 769412, 74 days before it is due

In shortEach US application has its clock. The Status Reporter writes one row per requirement and commitment: original and current schedule, the agency's status word, and an explanation with its evidence. Sam Patel in regulatory operations reviews, Omar signs, and the section exports to the annual report. The dashboard and settings keep the whole portfolio in view.

Seven commitment-tracking agents, and the people who sign every entry

In shortSeven specialist agents read, compare, route, watch and draft. None of them adds, changes or closes a record. A named person confirms each entry, a second person countersigns a change to a date or scope, and a commitment closes only when the agency confirms it.

Correspondence Reader to Status Reporter: what each agent does and never does

Regulatory lead, compliance, EU lead: who signs what on the commitment record

Electronic signatures record the signer's name, the time and the meaning, and every agent step and human decision goes on an audit trail you can export. These are controls that support your compliance with 21 CFR Part 11 and EU Annex 11; your validation stays yours. Botminds is SOC 2 Type II audited, and its information security is managed to ISO 27001. One rule is fixed: a commitment closes only when the agency confirms it.

Letters, minutes and responses in; a signed timeline and status tables out

Your RIM, mailbox and document repository stay where they are

Roles and maker-checker controls (one person prepares, another approves) apply across the portfolio, whether you run four products or a global catalog.

What a missed commitment costs you in penalties, public status and recovery hours

In shortNobody publishes what a late commitment costs a company, so the numbers that matter are yours. A few published figures frame them: how often reports arrive late, how often pediatric studies run behind, and the maximum civil penalty for a required study. Start with your own hours and your own near misses.

Status chasing, rework and lost promises: where the cost hides in your year

Costs no calculator counts: a partner audit, a stalled supplement, children still waiting

Hours back on status tables and letter intake, set against the tool's yearly cost

In shortPut in your own numbers. The return comes from four places: status table hours, letter intake, status chasing and recovery from late items. Promises found before they fall due are real value that no formula prices well, so the calculator leaves them out. Every default is an illustrative assumption to replace.

Four places commitment tracking pays back

Your yearly value from faster status tables and fewer late items

Is your commitments list ready for automation? Eight questions on documents, owners and signatures

In shortScore each question 0, 1 or 2. Nothing you choose leaves this page. The score says whether to build your baseline first, run a measured pilot or plan a full roll-out.

Testing commitment tracking software on your own minutes, with promises you planted

In shortAsk each vendor, us included, the same specific questions. Measure your baseline, test on your own documents with undertakings you already know about, and decide on three numbers. None of these steps commits you to anyone.

Twelve questions on reading, dates, signatures and exit

A one-product pilot in five steps

1. Read one product's file by hand. Every set of minutes and every response. Write down each undertaking. That list is your answer key.
2. Time your baseline: one status table and five letters, by step, including the emails.
3. Plant some tests: copy five documents and add promises you know about, including an undated one and one in a translated file.
4. Run in parallel for five weeks on live letters, with your regulatory lead signing every entry and one real status table drafted.
5. Decide with three numbers: undertakings found against your key, false items per document, and hours to a signed status table.

Undertakings found, false items and hours to a signed status table, plus two checks

Postmarketing requirements and commitments: sixteen questions regulatory teams search

In shortEach answer stands alone, so you can send one to a colleague.